Updates are available Correction dated 2023-07-20
Click to view Correction: https://doi.org/10.1186/s13148-023-01532-7
-
Authors
Bocova, Ledio
Hubens, Wouter
Engel, Cordula
Koschmieder, Steffen
Jost, Edgar
Wagner, Wolfgang
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (VIP+ Epi-Blood-Count)
Deutsche Forschungsgemeinschaft (363055819/GRK2415, WA1706/11-1, WA 1706/12-2 within CRU344/417911533, WA1706/14-1, SFB 1506/1)
ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (Prick-Me)
RWTH Aachen University
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 15 June 2023
First Online: 27 June 2023
Change Date: 20 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13148-023-01532-7
Declarations
:
: All blood samples were taken after informed and written consent, in accordance with the Declaration of Helsinki, as approved by the Ethic Committee of the Use of Human Subjects at the University of Aachen (Permit Number: EK099/14; healthy controls), or from the central biobank of the medical faculty of RWTH Aachen University (RWTH cBMB, EK 206/09; CB, mPB, apheresis, leukemia samples).
: Not applicable.
: RWTH Aachen University Medical School has claimed a patent for the epigenetic signature described in this manuscript. W.W. is cofounder of Cygenia GmbH that can provide service for various other epigenetic signatures (). Apart from this, the authors have no competing interests.
